4.7 Article

Immune response drives outcomes in prostate cancer: implications for immunotherapy

期刊

MOLECULAR ONCOLOGY
卷 15, 期 5, 页码 1358-1375

出版社

WILEY
DOI: 10.1002/1878-0261.12887

关键词

immune checkpoint blockade therapy; immune molecular subclassification system; immunotherapy; non‐ negative matrix factorization; prostate cancer

类别

资金

  1. National Natural Science Foundation of China [81802827, 81630019]
  2. Scientific Research Foundation of the Institute for Translational Medicine of Anhui Province [2017ZHYX02]
  3. Natural Science Foundation of Guangdong Province, China [2017A030313800]
  4. Key Project of Provincial Natural Science Research Project of Anhui Colleges [KJ2019A0278]
  5. Supporting Project for Distinguished Young Scholar of Anhui Colleges [gxyqZD2019018]
  6. 2017 Anhui Province special program for guiding local science and technology development by the central government [2017070802D148]

向作者/读者索取更多资源

A new immune molecular classifier was proposed in this study to classify prostate cancer patients into different immune-activated and immune-suppressed subtypes. The immune-activated subtype was found to be associated with favorable recurrence-free survival outcomes and was predicted to benefit more from anti-PD-1/PD-L1 therapy.
The heterogeneity of the immune microenvironment leads to different responses in immune checkpoint blockade therapy. We aimed to propose a robust molecular classification system to investigate the relevance of the immune microenvironment subtype and prognosis of prostate cancer patients, as well as the therapeutic response to immune checkpoint blockade therapy. A total of 1,557 prostate cancer patients were enrolled, including 69 real-world samples from our institute (titled the AHMU-PC cohort). The non-negative matrix factorization algorithm was employed to virtually microdissect patients. The immune enrichment was characterized by a high enrichment of T cell-, B cell-, NK cell-, and macrophage-associated signatures, by which patients were subclassified into nonimmune and immune classes. Subsequently, the immune class was dichotomized into immune-activated and immune-suppressed subtypes based on the stromal signature, represented by the activation of WNT/TGF-beta, TGF-beta 1, and C-ECM signatures. Approximately 14.9% to 24.3% of patients belonged to the immune-activated subtype, which was associated with favorable recurrence-free survival outcomes. In addition, patients in the immune-activated subtype were predicted to benefit more from anti-PD-1/PD-L1 therapy. In conclusion, our study identifies a novel immune molecular classifier that is closely related to clinical prognosis and provides novel insights into immunotherapeutic strategies for prostate cancer patients.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据